MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma

Document Type : Research Articles

Authors

1 Department of Biochemistry, Faculty of Science, Cairo University, Egypt.

2 Department of Chemistry, Faculty of Science, Cairo University, Egypt

3 Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt.

4 Department of Clinical pathology, National Liver Institute, Menoufia University, Egypt.

Abstract

Background: MicroRNAs are mentioned as a small non-coding RNAs groups and aberrant miRNA expression was
found in hepatocellular carcinoma (HCC) patients. Aim: To evaluate role of plasma MicroRNA-215 as a diagnostic
tool in HCC patients. Methods: A prospective study included 195 subjects: healthy controls (group I), cirrhotic patients
(group II), and patients with HCC (group III). Clinical examination, radiological and laboratory investigations which
included quantification of miR-215 by Real-time qPCR were done for all cases. Results: Spearman’s rank correlation
revealed that in HCC group, there was a negative correlation between MiRNA-215 and serum AFP levels and focal size
lesion (cm) (rs = -0.72, - 0.94 respectively, p<0.001). Receiver operating characteristics analysis for discrimination
between cirrhosis and HCC groups regarding microRNA-215 displayed 78.3% sensitivity, 88.0% specificity at cutoff
value of ≤ 1.90. Area under the curve (AUC) was 0.87 (p< 0.001). As regards AFP, it had a sensitivity of 81.7%, a
specificity of 66.7 at cutoff value of ≥ 11.50 (ng/mL). Conclusions: Plasma level of miR-215 may be a promising
biomarker in HCC diagnosis. Moreover, if miR-215 combined with AFP, it can be used as a diagnostic biomarker, for
early detection of HCC.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 20, Issue 9
September 2019
Pages 2723-2731

Files

History

  • Receive Date: 23 March 2019
  • Revise Date: 17 August 2019
  • Accept Date: 27 August 2019

Share

How to cite

Statistics